RLAY

Relay Therapeutics price target lowered to $16 from $20 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics (RLAY) to $16 from $20 and keeps a Buy rating on the shares. The firm says the Lirafugratinib out-licensing agreement “appears heavily back end-loaded.”

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on RLAY:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.